Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.verified

GLUE

Price:

$4.44

Market Cap:

$271.51M

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in he...[Read more]

Industry

Biotechnology

IPO Date

2021-06-24

Stock Exchange

NASDAQ

Ticker

GLUE

The PE Ratio as of July 2024 (TTM) for Monte Rosa Therapeutics, Inc. (GLUE) is -1.77

According to Monte Rosa Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.77. This represents a change of -28.44% compared to the average of -2.47 of the last 4 quarters.

Monte Rosa Therapeutics, Inc. (GLUE) Historical PE Ratio (quarterly & annually)

How has GLUE PE Ratio performed in the past?

The mean historical PE Ratio of Monte Rosa Therapeutics, Inc. over the last ten years is -32.18. The current -1.77 PE Ratio has changed 450.10% with respect to the historical average. Over the past ten years (40 quarters), GLUE's PE Ratio was at its highest in in the June 2021 quarter at -1.56. The PE Ratio was at its lowest in in the March 2020 quarter at -26.76.

Quarterly (TTM)
Annual

Average

-32.18

Median

-13.21

Minimum

-116.25

Maximum

-2.15

Monte Rosa Therapeutics, Inc. (GLUE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Monte Rosa Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual PE Ratio = -2.15

Minimum Annual Increase = -77.77%

Minimum Annual PE Ratio = -116.25

Quarterly (TTM)
Annual
YearPE RatioChange
2023-2.15-37.55%
2022-3.44-73.99%
2021-13.21-48.88%
2020-25.84-77.77%

Monte Rosa Therapeutics, Inc. (GLUE) Average PE Ratio

How has GLUE PE Ratio performed in the past?

The current PE Ratio of Monte Rosa Therapeutics, Inc. (GLUE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-6.26

5-year avg

-32.18

10-year avg

-32.18

Monte Rosa Therapeutics, Inc. (GLUE) PE Ratio vs. Peers

How is GLUE’s PE Ratio compared to its peers?

Monte Rosa Therapeutics, Inc.’s PE Ratio is greater than Nkarta, Inc. (-2.95), greater than Lyell Immunopharma, Inc. (-1.81), less than Generation Bio Co. (-1.21), greater than Sana Biotechnology, Inc. (-4.35), greater than Design Therapeutics, Inc. (-4.54), greater than Werewolf Therapeutics, Inc. (-2.77), less than Ikena Oncology, Inc. (-1.15), greater than Stoke Therapeutics, Inc. (-6.13), greater than Foghorn Therapeutics Inc. (-2.90), greater than Shattuck Labs, Inc. (-2.59), greater than Kymera Therapeutics, Inc. (-19.75), greater than Nurix Therapeutics, Inc. (-8.03), greater than Gracell Biotechnologies Inc. (-12.57), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Erasca, Inc. (-3.74),

Build a custom stock screener for Monte Rosa Therapeutics, Inc. (GLUE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monte Rosa Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monte Rosa Therapeutics, Inc. (GLUE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monte Rosa Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Monte Rosa Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for Monte Rosa Therapeutics, Inc. (GLUE)?

What is the highest PE Ratio for Monte Rosa Therapeutics, Inc. (GLUE)?

What is the 3-year average PE Ratio for Monte Rosa Therapeutics, Inc. (GLUE)?

What is the 5-year average PE Ratio for Monte Rosa Therapeutics, Inc. (GLUE)?

How does the current PE Ratio for Monte Rosa Therapeutics, Inc. (GLUE) compare to its historical average?